Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Prodrugxtend Pty Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being processed in 1 distinct art unit, reflecting a highly focused technical scope for the company's current patent activity. The concentration in 1 distinct art unit suggests that the prosecution strategy is tailored to a specific set of pharmaceutical or biotechnological examination standards.
The prosecution involves 1 distinct examiner, FAY, ZOHREH ALEMZADEH, who is also the busiest examiner with 1 pending action. Because there is only 1 distinct examiner and 1 pending office action, the company's entire active portfolio at the patent office is currently dependent on the review of this single individual. This creates a singular point of contact for all ongoing legal discussions.
For a company in the Biotechnology & Pharmaceuticals sector, having 1 pending office action indicates a very targeted approach to intellectual property. FAY, ZOHREH ALEMZADEH's role as the sole examiner for the 1 pending action means that the outcome of this specific matter will define the company's current success in the 1 distinct art unit. This streamlined prosecution profile allows for a dedicated focus on resolving the requirements of this individual examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18823760 | NOVEL FORMULATION AND TREATMENT METHODS | FAY, ZOHREH ALEMZADEH | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18823760 | NOVEL FORMULATION AND TREATMENT METHODS | FAY, ZOHREH ALEMZADEH | 1617 | §101DP | Non-Final OA | 31d overdue | Pending | Sep 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial